[1] 周远航,赵肸,郭影影,等.体外膜肺氧合治疗成人暴发性心肌炎的早期疗效及其对预后的影响[J].中华心血管病杂志,2022,50(3):270-276.DOI:10.3760/cma.j.cn112148-20210512-00419.
[2] Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care: Endorsed by the American Heart Association, the Cardiological Society of India, and Sociedad Latino Americana de Cardiología Intervencionista; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d'intervention[J]. J Am Coll Cardiol, 2015,65(19):2140-2141. DOI: 10.1016/j.jacc.2015.02.043.
[3] Abdul-Aziz MH, Roberts JA. Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter?[J]. Curr Opin Anaesthesiol, 2020,33(1):71-82. DOI: 10.1097/ACO.0000000000000810.
[4] Cook AM, Hatton-Kolpek J. Augmented renal clearance[J]. Pharmacotherapy, 2019,39(3):346-354. DOI: 10.1002/phar.2231.
[5] Hirai K, Ihara S, Kinae A, et al. Augmented renal clearance in pediatric patients with febrile neutropenia associated with Vancomycin clearance[J]. Ther Drug Monit, 2016,38(3):393-397. DOI: 10.1097/FTD.0000000000000270.
[6] Grootaert V, Willems L, Debaveye Y, et al. Augmented renal clearance in the critically ill: how to assess kidney function[J]. Ann Pharmacother, 2012,46(7-8):952-959. DOI: 10.1345/aph.1Q708.
[7] Álvarez R, López Cortés LE, Molina J, et al. Optimizing the clinical use of vancomycin[J]. Antimicrob Agents Chemother, 2016,60(5):2601-2609. DOI: 10.1128/AAC.03147-14.
[8] Hiraki Y, Onga T, Mizoguchi A, et al. Investigation of the prediction accuracy of vancomycin concentrations determined by patient-specific parameters as estimated by Bayesian analysis[J]. J Clin Pharm Ther, 2010,35(5):527-532. DOI: 10.1111/j.1365-2710.2009.01126.x.
[9] Fewel NP. Vancomycin-calculator[CP/OL].[2017-11-25](2017-12-12).http://Vancomycin Calculator-ClinCalc.com.
[10] 何志超,伍俊妍,邱凯锋. 万古霉素个体化给药临床药师指引[J].今日药学,2015,25(2):78-82.
[11] 国家卫生健康委办公厅.血管导管相关感染预防与控制指南(2021版)[J].传染病信息,2021,34(4):289-290,295.DOI:10.3969/j.issn.1007-8134.2021.04.001.
[12] Chaves F, Garnacho-Montero J, Del Pozo JL, et al. Diagnosis and treatment of catheter-related bloodstream infection: Clinical guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)[J]. Med Intensiva (Engl Ed), 2018,42(1):5-36. DOI: 10.1016/j.medin.2017.09.012.
[13] Juthani BK, Macfarlan J, Wu J, et al. Incidence of nosocomial infections in adult patients undergoing extracorporeal membrane oxygenation[J]. Heart Lung, 2018,47(6):626-630. DOI: 10.1016/j.hrtlng.2018.07.004.
[14] 龙村.体外膜肺氧合循环支持专家共识[J].中国体外循环杂志,2014,12(2):65-67.DOI:10.13498/j.cnki.chin.j.ecc.2014.02.01.
[15] Esteve F, Pujol M, Ariza J, et al. Impacto de un programa de prevención de la bacteriemia relacionada con el catéter en una unidad de cuidados intensivos de un hospital terciario [Impact of a prevention program for catheter-related bloodstream infection in the intensive care unit of a tertiary hospital][J]. Enferm Infecc Microbiol Clin, 2009,27(10):561-565. doi: 10.1016/j.eimc.2009.03.004.
[16] D'Amico R, Pifferi S, Leonetti C, et al. Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials[J]. BMJ, 1998,316(7140):1275-1285. DOI: 10.1136/bmj. 316.7140.1275.
[17] Shekar K, Fraser JF, Smith MT, et al. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation[J]. J Crit Care, 2012,27(6):741.e9-18. DOI: 10.1016/j.jcrc.2012.02.013.
[18] Bessereau J, Chenaitia H, Michelet P, et al. Acute respiratory distress syndrome following 2009 H1N1 virus pandemic: when ECMO come to the patient bedside[J]. Ann Fr Anesth Reanim, 2010,29(2):165-166. DOI: 10.1016/j.annfar.2010.01.008.
[19] Stocker CF, Horton SB. Anticoagulation strategies and difficulties in neonatal and paediatric extracorporeal membrane oxygenation (ECMO)[J]. Perfusion, 2016,31(2):95-102. DOI: 10.1177/0267659115590626.
[20] Shekar K, Roberts JA, Ghassabian S, et al. Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?[J]. J Antimicrob Chemother, 2013,68(3):726-727. DOI: 10.1093/jac/dks435.
[21] Ha MA, Sieg AC. Evaluation of altered drug pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation[J]. Pharmacotherapy, 2017,37(2):221-235. DOI: 10.1002/phar.1882.
[22] Herrera Hidalgo L, Guisado Gil AB, Gil Navarro MV, et al. Therapeutic drug monitoring of vancomycin in a patient on extracorporeal membrane oxygenation therapy in intensive care unit[J]. Eur J Clin Pharmacol, 2018,74(8):1093-1094. DOI: 10.1007/s00228-018-2473-x.
[23] Yang CJ, Wu CW, Wu CC. Effect of extracorporeal membrane oxygenation on the new vancomycin dosing regimen in critically ill patients receiving continuous venovenous hemofiltration[J]. Ther Drug Monit, 2018,40(3):310-314. DOI: 10.1097/FTD.0000000000000495.
[24] Moore JN, Healy JR, Thoma BN, et al. A population pharmacokinetic model for vancomycin in adult patients receiving extracorporeal membrane oxygenation therapy[J]. CPT Pharmacometrics Syst Pharmacol, 2016,5(9):495-502. DOI: 10.1002/psp4.12112.
[25] Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation[J]. Br J Clin Pharmacol, 2005,60(3):265-275. DOI: 10.1111/j.1365-2125.2005.02432.x.
[26] Park SJ, Yang JH, Park HJ, et al. Trough concentrations of vancomycin in patients undergoing extracorporeal membrane oxygenation[J]. PLoS One, 2015,10(11):e0141016. DOI: 10.1371/journal.pone.0141016.
[27] Abdul-Aziz MH, Roberts JA. Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter?[J]. Curr Opin Anaesthesiol, 2020,33(1):71-82. DOI: 10.1097/ACO.0000000000000810.
[28] Hirai K, Ihara S, Kinae A, et al. Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance[J]. Ther Drug Monit, 2016,38(3):393-397. DOI: 10.1097/FTD.0000000000000270.
[29] Sime FB, Udy AA, Roberts JA. Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization[J]. Curr Opin Pharmacol, 2015, 24:1-6. DOI: 10.1016/j.coph. 2015.06.002.
[30] Chen Y, Liu L, Zhu M. Effect of augmented renal clearance on the therapeutic drug monitoring of vancomycin in patients after neurosurgery[J]. J Int Med Res, 2020,48(10):300060520949076. DOI: 10.1177/0300060520949076.
[31] Hirai K, Ishii H, Shimoshikiryo T, et al. Augmented renal clearance in patients with febrile neutropenia is associated with increased risk for subtherapeutic concentrations of vancomycin[J]. Ther Drug Monit, 2016,38(6):706-710. DOI: 10.1097/FTD.0000000000000346.
[32] Udy AA, Morton FJ, Nguyen-Pham S, et al. A comparison of CKD-EPI estimated glomerular filtration rate and measured creatinine clearance in recently admitted critically ill patients with normal plasma creatinine concentrations[J]. BMC Nephrol, 2013,14:250. DOI: 10. 1186/1471- 2369-14-250.
[33] Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, et al. Augmented renal clearance in critically ill patients: a systematic review[J]. Clin Pharmacokinet, 2018,57(9):1107-1121. DOI: 10.1007/s40262-018-0636-7.
|